<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20241104111323&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20241104111323&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Mon, 04 Nov 2024 16:13:24 +0000</lastbuilddate>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39492722/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 4. doi: 10.1161/CIRCULATIONAHA.124.069556. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) level, LDL-C level, and ASCVD risk at different thresholds is not well defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A participant-level meta-analysis of 27 658 participants enrolled in 6 placebo-controlled statin trials was performed to assess the association of LDL-C and Lp(a) levels with risk of fatal or nonfatal coronary heart disease events, stroke, or any coronary or carotid revascularization (ASCVD). The multivariable-adjusted association between baseline Lp(a) level and ASCVD risk was modeled continuously using generalized additive models, and the association between baseline LDL-C level and ASCVD risk by baseline Lp(a) level by Cox proportional hazards models with random effects. The joint association between Lp(a) level and statin-achieved LDL-C level with ASCVD risk was evaluated using Cox proportional hazards models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with an Lp(a) level of 5 mg/dL, increasing levels of Lp(a) were log-linearly associated with ASCVD risk in statin- and placebo-treated patients. Among statin-treated individuals, those with Lp(a) level >;50 mg/dL (≈125 nmol/L) had increased risk across all quartiles of achieved LDL-C level and absolute change in LDL-C level. Even among those with the lowest quartile of achieved LDL-C level (3.1-77.0 mg/dL), those with Lp(a) level >;50 mg/dL had greater ASCVD risk (hazard ratio, 1.38 [95% CI, 1.06-1.79]) than those with Lp(a) level ≤50 mg/dL. The greatest risk was observed with both Lp(a) level >;50 mg/dL and LDL-C level in the fourth quartile (hazard ratio, 1.90 [95% CI, 1.46-2.48]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39492722/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39492722</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069556>10.1161/CIRCULATIONAHA.124.069556</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39492722</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Harpreet S Bhatia</dc:creator>
<dc:creator>Simon Wandel</dc:creator>
<dc:creator>Peter Willeit</dc:creator>
<dc:creator>Anastasia Lesogor</dc:creator>
<dc:creator>Keith Bailey</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Paul Nestel</dc:creator>
<dc:creator>John Simes</dc:creator>
<dc:creator>Andrew Tonkin</dc:creator>
<dc:creator>Gregory G Schwartz</dc:creator>
<dc:creator>Helen Colhoun</dc:creator>
<dc:creator>Christoph Wanner</dc:creator>
<dc:creator>Sotirios Tsimikas</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis</dc:title>
<dc:identifier>pmid:39492722</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069556</dc:identifier>
</item>
<item>
<title>Kindlin-2 Phase Separation in Response to Flow Controls Vascular Stability</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39492718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Collectively, our study elucidates that mechanical force induces arginine methylation of Kindlin-2, thereby regulating vascular stability through its impact on Kindlin-2 LLPS. Targeting Kindlin-2 arginine methylation emerges as a promising hemodynamic-based strategy for treating vascular disorders and atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Nov 4. doi: 10.1161/CIRCRESAHA.124.324773. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atheroprotective shear stress preserves endothelial barrier function, while atheroprone shear stress enhances endothelial permeability. Yet, the underlying mechanisms through which distinct flow patterns regulate EC integrity remain to be clarified. This study aimed to investigate the involvement of Kindlin-2, a key component of focal adhesion and endothelial adherens junctions crucial for regulating endothelial cell (EC) integrity and vascular stability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Mouse models of atherosclerosis in EC-specific <i>Kindlin-2</i> knockout mice (<i>Kindlin-2</i><sup><i>iΔEC</i></sup>) were used to study the role of Kindlin-2 in atherogenesis. Pulsatile shear (2±4 dynes/cm<sup>2</sup>) or oscillatory shear (0.5±4 dynes/cm<sup>2</sup>) were applied to culture ECs. Live-cell imaging, fluorescence recovery after photobleaching assay, and optoDroplet assay were used to study the liquid-liquid phase separation (LLPS) of Kindlin-2. Co-immunoprecipitation, mutagenesis, proximity ligation assay, and transendothelial electrical resistance assay were used to explore the underlying mechanism of flow-regulated Kindlin-2 function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that Kindlin-2 localization is altered under different flow patterns. <i>Kindlin-2</i><sup><i>iΔEC</i></sup> mice showed heightened vascular permeability. <i>Kindlin-2</i><sup><i>iΔEC</i></sup> were bred onto <i>ApoE</i><sup><i>-/-</i></sup> mice to generate <i>Kindlin-2</i><sup><i>iΔEC</i></sup>; <i>ApoE</i><sup><i>-</i></sup><sup><i>/-</i></sup> mice, which displayed a significant increase in atherosclerosis lesions. In vitro data showed that in ECs, Kindlin-2 underwent LLPS, a critical process for proper focal adhesion assembly, maturation, and junction formation. Mass spectrometry analysis revealed that oscillatory shear increased arginine methylation of Kindlin-2, catalyzed by PRMT5 (protein arginine methyltransferase 5). Functionally, arginine hypermethylation inhibits Kindlin-2 LLPS, impairing focal adhesion assembly and junction maturation. Notably, we identified R290 of Kindlin-2 as a crucial residue for LLPS and a key site for arginine methylation. Finally, pharmacologically inhibiting arginine methylation reduces EC activation and plaque formation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Collectively, our study elucidates that mechanical force induces arginine methylation of Kindlin-2, thereby regulating vascular stability through its impact on Kindlin-2 LLPS. Targeting Kindlin-2 arginine methylation emerges as a promising hemodynamic-based strategy for treating vascular disorders and atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02783300.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39492718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39492718</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324773>10.1161/CIRCRESAHA.124.324773</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39492718</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Nina Ma</dc:creator>
<dc:creator>Fangfang Wu</dc:creator>
<dc:creator>Jiayu Liu</dc:creator>
<dc:creator>Ziru Wu</dc:creator>
<dc:creator>Lu Wang</dc:creator>
<dc:creator>Bochuan Li</dc:creator>
<dc:creator>Yuming Liu</dc:creator>
<dc:creator>Xue Dong</dc:creator>
<dc:creator>Junhao Hu</dc:creator>
<dc:creator>Xi Fang</dc:creator>
<dc:creator>Heng Zhang</dc:creator>
<dc:creator>Ding Ai</dc:creator>
<dc:creator>Jing Zhou</dc:creator>
<dc:creator>Xiaohong Wang</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Kindlin-2 Phase Separation in Response to Flow Controls Vascular Stability</dc:title>
<dc:identifier>pmid:39492718</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324773</dc:identifier>
</item>
<item>
<title>Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39492713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Multicomponent activity intervention during and after allo-SCT is beneficial for preserving patient cardiorespiratory fitness and exercise cardiac function. These results may have important implications for cardiovascular morbidity and mortality after allo-SCT.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 4. doi: 10.1161/CIRCULATIONAHA.124.070709. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be complicated by cardiac dysfunction and exercise intolerance impacting quality of life and longevity. We conducted a randomized controlled trial testing whether a multicomponent activity intervention could attenuate reductions in cardiorespiratory fitness and exercise cardiac function (co-primary end points) in adults undergoing allo-SCT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Sixty-two adults scheduled for allo-SCT were randomized to a 4-month activity program (n=30) or usual care (UC; n=32). Activity comprised multicomponent exercise training (3 days/week) and sedentary time reduction (≥30 min/day) program and was delivered throughout hospitalization (≈4 weeks) and for 12 weeks after discharge. Physiological assessments conducted before admission and at 12 weeks after discharge included cardiopulmonary exercise testing to quantify peak oxygen uptake ([Formula: see text]), exercise cardiac magnetic resonance imaging for peak cardiac volume (CI<sub>peak</sub>) and stroke volume (SVI<sub>peak</sub>) index, echocardiography-derived left ventricular ejection fraction and global longitudinal strain, and cardiac biomarkers (cTn-I [troponin-I] and BNP [B-type natriuretic peptide]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Fifty-two participants (84%) completed follow-up (25 activity and 27 UC); median (interquartile range [IQR]) adherence to the activity program was 74% (41-96%). There was a marked decline in [Formula: see text] in the UC program (-3.4 mL‧kg<sup>-1</sup>‧min<sup>-1</sup> [95% CI, -4.9 to -1.8]) that was attenuated with activity (-0.9 mL‧kg<sup>-1‧</sup>min<sup>-1</sup> [95% CI, -2.5 to 0.8]; interaction <i>P</i>=0.029). Activity preserved exercise cardiac function, with preservation of CI<sub>peak</sub> (0.30 L‧min<sup>-1</sup>‧m<sup>-</sup><sup>2</sup> [95% CI, -0.34 to 0.41]) and SVI<sub>peak</sub> (0.6 mL/m<sup>2</sup> [95% CI, -1.3 to 2.5]), both of which declined with UC (CI<sub>peak</sub>, -0.68 L‧min<sup>-1</sup>‧m<sup>-</sup><sup>2</sup> [95% CI, -1.3 to -0.32]; interaction <i>P</i>=0.008; SVI<sub>peak</sub>, -2.7 mL/m<sup>2</sup> [95% CI, -4.6 to -0.9]; interaction <i>P=</i>0.014). There were no treatment effects of activity on cardiac biomarkers or echocardiographic indices.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Multicomponent activity intervention during and after allo-SCT is beneficial for preserving patient cardiorespiratory fitness and exercise cardiac function. These results may have important implications for cardiovascular morbidity and mortality after allo-SCT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://anzctr.org.au/; Unique identifier: ACTRN12619000741189.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39492713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39492713</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070709>10.1161/CIRCULATIONAHA.124.070709</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39492713</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Hayley T Dillon</dc:creator>
<dc:creator>Nicholas J Saner</dc:creator>
<dc:creator>Tegan Ilsley</dc:creator>
<dc:creator>David S Kliman</dc:creator>
<dc:creator>Stephen J Foulkes</dc:creator>
<dc:creator>Christian J Brakenridge</dc:creator>
<dc:creator>Andrew Spencer</dc:creator>
<dc:creator>Sharon Avery</dc:creator>
<dc:creator>Piet Claus</dc:creator>
<dc:creator>David W Dunstan</dc:creator>
<dc:creator>Robin M Daly</dc:creator>
<dc:creator>Steve F Fraser</dc:creator>
<dc:creator>Neville Owen</dc:creator>
<dc:creator>Brigid M Lynch</dc:creator>
<dc:creator>Bronwyn A Kingwell</dc:creator>
<dc:creator>Andre La Gerche</dc:creator>
<dc:creator>Erin J Howden</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial</dc:title>
<dc:identifier>pmid:39492713</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070709</dc:identifier>
</item>
<item>
<title>Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39490700/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In FINEARTS-HF, a population at low risk of adverse kidney outcomes, finerenone did not significantly modify the kidney composite outcomes. Finerenone led to a greater reduction in initial eGFR, but did not result in a significant difference in chronic eGFR slope, vs. placebo. Finerenone led to early and sustained reductions in albuminuria and reduced the risk of new-onset micro- and macroalbuminuria.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)10252-5. doi: 10.1016/j.jacc.2024.10.091. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Finerenone has kidney protective effects in patients with chronic kidney disease (CKD) with type 2 diabetes, but effects on kidney outcomes in patients with heart failure (HF) with and without diabetes and/or CKD are not known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Examine the effects of finerenone on kidney outcomes in FINEARTS-HF, a randomized trial of finerenone vs. placebo among patients with HF with mildly reduced or preserved ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We explored the effects of finerenone on the secondary outcome of a sustained ≥50% eGFR decline or kidney failure (sustained eGFR decline &lt;15 mL/min/1.73 m<sup>2</sup>; initiation of maintenance dialysis; renal transplant). In this prespecified analysis, we also report effects of finerenone on: 1) sustained ≥57% eGFR decline or kidney failure; 2) eGFR slope; 3) changes in urine albumin/creatinine ratio (UACR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6,001 participants, mean baseline eGFR was 62 ±20mL/min/1.73m<sup>2</sup>; 48% had eGFR &lt;60mL/min/1.73m<sup>2</sup>. Overall, 5,797 had baseline UACR data (median 18 [7,67]mg/g). Over 2.6 years median follow-up, the incidence of the composite kidney outcome (≥50% eGFR decline or kidney failure) was numerically, but non-significantly, higher for finerenone vs. placebo (75 vs. 55 events; HR 1.33; 95%CI 0.94, 1.89). Similar results were observed for the composite of ≥57% eGFR decline or kidney failure (41 vs. 31 events; HR 1.28; 95%CI 0.80, 2.05), though the overall event frequency was relatively low. During the first 3 months, finerenone led to an acute decline in eGFR of -2.9 mL/min/1.73m<sup>2</sup> (95%CI -3.4, -2.4) but did not alter chronic (from 3 months) eGFR slope (+0.2 mL/min/1.73m<sup>2</sup>/year; 95%CI -0.1, +0.4), vs. placebo. The difference in total slope was -0.7 (95%CI -0.9 to -0.4) mL/min/1.73 m<sup>2</sup>/year. Finerenone reduced UACR by 30% (95%CI 25%, 34%) over 6 months vs. placebo, an effect that persisted throughout follow-up. Finerenone reduced the risk of new-onset of micro- and macroalbuminuria by 24% (HR 0.76; 95%CI 0.68, 0.83) and 38% (HR 0.62; 95%CI 0.53, 0.73), respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In FINEARTS-HF, a population at low risk of adverse kidney outcomes, finerenone did not significantly modify the kidney composite outcomes. Finerenone led to a greater reduction in initial eGFR, but did not result in a significant difference in chronic eGFR slope, vs. placebo. Finerenone led to early and sustained reductions in albuminuria and reduced the risk of new-onset micro- and macroalbuminuria.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39490700/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39490700</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.091>10.1016/j.jacc.2024.10.091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39490700</guid>
<pubDate>Sun, 03 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Finnian R Mc Causland</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Meike Brinker</dc:creator>
<dc:creator>Robert Perkins</dc:creator>
<dc:creator>Markus F Scheerer</dc:creator>
<dc:creator>Patrick Schloemer</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-11-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial</dc:title>
<dc:identifier>pmid:39490700</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.091</dc:identifier>
</item>
<item>
<title>Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39488207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>Targeted protein degradation (TPD) utilizes molecular glues or proteolysis-targeting chimeras (PROTACs) to eliminate disease-causing proteins by promoting their interaction with E3 ubiquitin ligases. Current TPD approaches are limited by reliance on a small number of constitutively active E3 ubiquitin ligases. Here, we report that (S)-ACE-OH, a metabolite of the antipsychotic drug acepromazine, acts as a molecular glue to induce an interaction between the E3 ubiquitin ligase TRIM21 and the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 30:S0092-8674(24)01197-8. doi: 10.1016/j.cell.2024.10.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Targeted protein degradation (TPD) utilizes molecular glues or proteolysis-targeting chimeras (PROTACs) to eliminate disease-causing proteins by promoting their interaction with E3 ubiquitin ligases. Current TPD approaches are limited by reliance on a small number of constitutively active E3 ubiquitin ligases. Here, we report that (S)-ACE-OH, a metabolite of the antipsychotic drug acepromazine, acts as a molecular glue to induce an interaction between the E3 ubiquitin ligase TRIM21 and the nucleoporin NUP98, leading to the degradation of nuclear pore proteins and disruption of nucleocytoplasmic trafficking. Functionalization of acepromazine into PROTACs enabled selective degradation of multimeric proteins, such as those within biomolecular condensates, while sparing monomeric proteins. This selectivity is consistent with the requirement of substrate-induced clustering for TRIM21 activation. As aberrant protein assemblies cause diseases such as autoimmunity, neurodegeneration, and cancer, our findings highlight the potential of TRIM21-based multimer-selective degraders as a strategy to tackle the direct causes of these diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39488207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39488207</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.015>10.1016/j.cell.2024.10.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39488207</guid>
<pubDate>Sat, 02 Nov 2024 06:00:00 -0400</pubDate>
<dc:creator>Panrui Lu</dc:creator>
<dc:creator>Yalong Cheng</dc:creator>
<dc:creator>Lei Xue</dc:creator>
<dc:creator>Xintong Ren</dc:creator>
<dc:creator>Xilong Xu</dc:creator>
<dc:creator>Chenglong Chen</dc:creator>
<dc:creator>Longzhi Cao</dc:creator>
<dc:creator>Jiaojiao Li</dc:creator>
<dc:creator>Qingcui Wu</dc:creator>
<dc:creator>Shan Sun</dc:creator>
<dc:creator>Junjie Hou</dc:creator>
<dc:creator>Wei Jia</dc:creator>
<dc:creator>Wei Wang</dc:creator>
<dc:creator>Yan Ma</dc:creator>
<dc:creator>Zhaodi Jiang</dc:creator>
<dc:creator>Chao Li</dc:creator>
<dc:creator>Xiangbing Qi</dc:creator>
<dc:creator>Niu Huang</dc:creator>
<dc:creator>Ting Han</dc:creator>
<dc:date>2024-11-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders</dc:title>
<dc:identifier>pmid:39488207</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.015</dc:identifier>
</item>
<item>
<title>Beyond Prognosis: The Vital Role of Quality of Life after Transcatheter Tricuspid Valve Replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39486558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)10055-1. doi: 10.1016/j.jacc.2024.10.087. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39486558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39486558</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.087>10.1016/j.jacc.2024.10.087</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39486558</guid>
<pubDate>Fri, 01 Nov 2024 06:00:00 -0400</pubDate>
<dc:creator>Domenico Angellotti</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2024-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Beyond Prognosis: The Vital Role of Quality of Life after Transcatheter Tricuspid Valve Replacement</dc:title>
<dc:identifier>pmid:39486558</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.087</dc:identifier>
</item>
<item>
<title>Advances in Transcatheter Tricuspid Valve Interventions-Implications for Health Policy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39486557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)10057-5. doi: 10.1016/j.jacc.2024.10.089. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39486557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39486557</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.089>10.1016/j.jacc.2024.10.089</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39486557</guid>
<pubDate>Fri, 01 Nov 2024 06:00:00 -0400</pubDate>
<dc:creator>Kushal T Kadakia</dc:creator>
<dc:creator>Sanket S Dhruva</dc:creator>
<dc:date>2024-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Advances in Transcatheter Tricuspid Valve Interventions-Implications for Health Policy</dc:title>
<dc:identifier>pmid:39486557</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.089</dc:identifier>
</item>
<item>
<title>Transcatheter Interventions in Tricuspid Regurgitation: Shifting the focus beyond Quantity of Life to Quality of Life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39486556/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 18:S0735-1097(24)10053-8. doi: 10.1016/j.jacc.2024.10.085. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39486556/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39486556</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.085>10.1016/j.jacc.2024.10.085</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39486556</guid>
<pubDate>Fri, 01 Nov 2024 06:00:00 -0400</pubDate>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>Celina Yong</dc:creator>
<dc:creator>Rasha Al-Lamee</dc:creator>
<dc:date>2024-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Interventions in Tricuspid Regurgitation: Shifting the focus beyond Quantity of Life to Quality of Life</dc:title>
<dc:identifier>pmid:39486556</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.085</dc:identifier>
</item>
<item>
<title>Empowering biomedical discovery with AI agents</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39486399/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>We envision "AI scientists" as systems capable of skeptical learning and reasoning that empower biomedical research through collaborative agents that integrate AI models and biomedical tools with experimental platforms. Rather than taking humans out of the discovery process, biomedical AI agents combine human creativity and expertise with AI's ability to analyze large datasets, navigate hypothesis spaces, and execute repetitive tasks. AI agents are poised to be proficient in various tasks,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 31;187(22):6125-6151. doi: 10.1016/j.cell.2024.09.022.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">We envision "AI scientists" as systems capable of skeptical learning and reasoning that empower biomedical research through collaborative agents that integrate AI models and biomedical tools with experimental platforms. Rather than taking humans out of the discovery process, biomedical AI agents combine human creativity and expertise with AI's ability to analyze large datasets, navigate hypothesis spaces, and execute repetitive tasks. AI agents are poised to be proficient in various tasks, planning discovery workflows and performing self-assessment to identify and mitigate gaps in their knowledge. These agents use large language models and generative models to feature structured memory for continual learning and use machine learning tools to incorporate scientific knowledge, biological principles, and theories. AI agents can impact areas ranging from virtual cell simulation, programmable control of phenotypes, and the design of cellular circuits to developing new therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39486399/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39486399</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.022>10.1016/j.cell.2024.09.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39486399</guid>
<pubDate>Fri, 01 Nov 2024 06:00:00 -0400</pubDate>
<dc:creator>Shanghua Gao</dc:creator>
<dc:creator>Ada Fang</dc:creator>
<dc:creator>Yepeng Huang</dc:creator>
<dc:creator>Valentina Giunchiglia</dc:creator>
<dc:creator>Ayush Noori</dc:creator>
<dc:creator>Jonathan Richard Schwarz</dc:creator>
<dc:creator>Yasha Ektefaie</dc:creator>
<dc:creator>Jovana Kondic</dc:creator>
<dc:creator>Marinka Zitnik</dc:creator>
<dc:date>2024-11-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Empowering biomedical discovery with AI agents</dc:title>
<dc:identifier>pmid:39486399</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.022</dc:identifier>
</item>
<item>
<title>Viroid-like colonists of human microbiomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39481381/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>Here, we describe "obelisks," a class of heritable RNA elements sharing several properties: (1) apparently circular RNA ∼1 kb genome assemblies, (2) predicted rod-like genome-wide secondary structures, and (3) open reading frames encoding a novel "Oblin" protein superfamily. A subset of obelisks includes a variant hammerhead self-cleaving ribozyme. Obelisks form their own phylogenetic group without detectable similarity to known biological agents. Surveying globally, we identified 29,959...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 23:S0092-8674(24)01091-2. doi: 10.1016/j.cell.2024.09.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Here, we describe "obelisks," a class of heritable RNA elements sharing several properties: (1) apparently circular RNA ∼1 kb genome assemblies, (2) predicted rod-like genome-wide secondary structures, and (3) open reading frames encoding a novel "Oblin" protein superfamily. A subset of obelisks includes a variant hammerhead self-cleaving ribozyme. Obelisks form their own phylogenetic group without detectable similarity to known biological agents. Surveying globally, we identified 29,959 distinct obelisks (clustered at 90% sequence identity) from diverse ecological niches. Obelisks are prevalent in human microbiomes, with detection in ∼7% (29/440) and ∼50% (17/32) of queried stool and oral metatranscriptomes, respectively. We establish Streptococcus sanguinis as a cellular host of a specific obelisk and find that this obelisk's maintenance is not essential for bacterial growth. Our observations identify obelisks as a class of diverse RNAs of yet-to-be-determined impact that have colonized and gone unnoticed in human and global microbiomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39481381/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39481381</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.033>10.1016/j.cell.2024.09.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39481381</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ivan N Zheludev</dc:creator>
<dc:creator>Robert C Edgar</dc:creator>
<dc:creator>Maria Jose Lopez-Galiano</dc:creator>
<dc:creator>Marcos de la Peña</dc:creator>
<dc:creator>Artem Babaian</dc:creator>
<dc:creator>Ami S Bhatt</dc:creator>
<dc:creator>Andrew Z Fire</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Viroid-like colonists of human microbiomes</dc:title>
<dc:identifier>pmid:39481381</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.033</dc:identifier>
</item>
<item>
<title>Ovarian cancer-derived IL-4 promotes immunotherapy resistance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39481380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>Ovarian cancer is resistant to immunotherapy, and this is influenced by the immunosuppressed tumor microenvironment (TME) dominated by macrophages. Resistance is also affected by intratumoral heterogeneity, whose development is poorly understood. To identify regulators of ovarian cancer immunity, we employed a spatial functional genomics screen (Perturb-map), focused on receptor/ligands hypothesized to be involved in tumor-macrophage communication. Perturb-map recapitulated tumor heterogeneity...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 25:S0092-8674(24)01154-1. doi: 10.1016/j.cell.2024.10.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ovarian cancer is resistant to immunotherapy, and this is influenced by the immunosuppressed tumor microenvironment (TME) dominated by macrophages. Resistance is also affected by intratumoral heterogeneity, whose development is poorly understood. To identify regulators of ovarian cancer immunity, we employed a spatial functional genomics screen (Perturb-map), focused on receptor/ligands hypothesized to be involved in tumor-macrophage communication. Perturb-map recapitulated tumor heterogeneity and revealed that interleukin-4 (IL-4) promotes resistance to anti-PD-1. We find ovarian cancer cells are the key source of IL-4, which directs the formation of an immunosuppressive TME via macrophage control. IL-4 loss was not compensated by nearby IL-4-expressing clones, revealing short-range regulation of TME composition dictating tumor evolution. Our studies show heterogeneous TMEs can emerge from localized altered expression of cancer-derived cytokines/chemokines that establish immune-rich and immune-excluded neighborhoods, which drive clone selection and immunotherapy resistance. They also demonstrate the potential of targeting IL-4 signaling to enhance ovarian cancer response to immunotherapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39481380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39481380</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.006>10.1016/j.cell.2024.10.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39481380</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gurkan Mollaoglu</dc:creator>
<dc:creator>Alexander Tepper</dc:creator>
<dc:creator>Chiara Falcomatà</dc:creator>
<dc:creator>Hunter T Potak</dc:creator>
<dc:creator>Luisanna Pia</dc:creator>
<dc:creator>Angelo Amabile</dc:creator>
<dc:creator>Jaime Mateus-Tique</dc:creator>
<dc:creator>Noam Rabinovich</dc:creator>
<dc:creator>Matthew D Park</dc:creator>
<dc:creator>Nelson M LaMarche</dc:creator>
<dc:creator>Rachel Brody</dc:creator>
<dc:creator>Lindsay Browning</dc:creator>
<dc:creator>Jia-Ren Lin</dc:creator>
<dc:creator>Dmitriy Zamarin</dc:creator>
<dc:creator>Peter K Sorger</dc:creator>
<dc:creator>Sandro Santagata</dc:creator>
<dc:creator>Miriam Merad</dc:creator>
<dc:creator>Alessia Baccarini</dc:creator>
<dc:creator>Brian D Brown</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Ovarian cancer-derived IL-4 promotes immunotherapy resistance</dc:title>
<dc:identifier>pmid:39481380</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.006</dc:identifier>
</item>
<item>
<title>Multiscale organization of neuronal activity unifies scale-dependent theories of brain function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39481379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>Brain recordings collected at different resolutions support distinct signatures of neural coding, leading to scale-dependent theories of brain function. Here, we show that these disparate signatures emerge from a heavy-tailed, multiscale functional organization of neuronal activity observed across calcium-imaging recordings collected from the whole brains of zebrafish and C. elegans as well as from sensory regions in Drosophila, mice, and macaques. Network simulations demonstrate that this...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 26:S0092-8674(24)01152-8. doi: 10.1016/j.cell.2024.10.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Brain recordings collected at different resolutions support distinct signatures of neural coding, leading to scale-dependent theories of brain function. Here, we show that these disparate signatures emerge from a heavy-tailed, multiscale functional organization of neuronal activity observed across calcium-imaging recordings collected from the whole brains of zebrafish and C. elegans as well as from sensory regions in Drosophila, mice, and macaques. Network simulations demonstrate that this conserved hierarchical structure enhances information processing. Finally, we find that this organization is maintained despite significant cross-scale reconfiguration of cellular coordination during behavior. Our findings suggest that this nonlinear organization of neuronal activity is a universal principle conserved for its ability to adaptively link behavior to neural dynamics across multiple spatiotemporal scales while balancing functional resiliency and information processing efficiency.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39481379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39481379</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.004>10.1016/j.cell.2024.10.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39481379</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Brandon R Munn</dc:creator>
<dc:creator>Eli J Müller</dc:creator>
<dc:creator>Itia Favre-Bulle</dc:creator>
<dc:creator>Ethan Scott</dc:creator>
<dc:creator>Joseph T Lizier</dc:creator>
<dc:creator>Michael Breakspear</dc:creator>
<dc:creator>James M Shine</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multiscale organization of neuronal activity unifies scale-dependent theories of brain function</dc:title>
<dc:identifier>pmid:39481379</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.004</dc:identifier>
</item>
<item>
<title>IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39481378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>The autophagy-lysosome system directs the degradation of a wide variety of cargo and is also involved in tumor progression. Here, we show that the immunity-related GTPase family Q protein (IRGQ), an uncharacterized protein to date, acts in the quality control of major histocompatibility complex class I (MHC class I) molecules. IRGQ directs misfolded MHC class I toward lysosomal degradation through its binding mode to GABARAPL2 and LC3B. In the absence of IRGQ, free MHC class I heavy chains do...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 21:S0092-8674(24)01148-6. doi: 10.1016/j.cell.2024.09.048. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The autophagy-lysosome system directs the degradation of a wide variety of cargo and is also involved in tumor progression. Here, we show that the immunity-related GTPase family Q protein (IRGQ), an uncharacterized protein to date, acts in the quality control of major histocompatibility complex class I (MHC class I) molecules. IRGQ directs misfolded MHC class I toward lysosomal degradation through its binding mode to GABARAPL2 and LC3B. In the absence of IRGQ, free MHC class I heavy chains do not only accumulate in the cell but are also transported to the cell surface, thereby promoting an immune response. Mice and human patients suffering from hepatocellular carcinoma show improved survival rates with reduced IRGQ levels due to increased reactivity of CD8+ T cells toward IRGQ knockout tumor cells. Thus, we reveal IRGQ as a regulator of MHC class I quality control, mediating tumor immune evasion.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39481378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39481378</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.048>10.1016/j.cell.2024.09.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39481378</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Lina Herhaus</dc:creator>
<dc:creator>Uxía Gestal-Mato</dc:creator>
<dc:creator>Vinay V Eapen</dc:creator>
<dc:creator>Igor Mačinković</dc:creator>
<dc:creator>Henry J Bailey</dc:creator>
<dc:creator>Cristian Prieto-Garcia</dc:creator>
<dc:creator>Mohit Misra</dc:creator>
<dc:creator>Anne-Claire Jacomin</dc:creator>
<dc:creator>Aparna Viswanathan Ammanath</dc:creator>
<dc:creator>Ivan Bagarić</dc:creator>
<dc:creator>Jolina Michaelis</dc:creator>
<dc:creator>Joshua Vollrath</dc:creator>
<dc:creator>Ramachandra M Bhaskara</dc:creator>
<dc:creator>Georg Bündgen</dc:creator>
<dc:creator>Adriana Covarrubias-Pinto</dc:creator>
<dc:creator>Koraljka Husnjak</dc:creator>
<dc:creator>Jonathan Zöller</dc:creator>
<dc:creator>Ajami Gikandi</dc:creator>
<dc:creator>Sara Ribičić</dc:creator>
<dc:creator>Tobias Bopp</dc:creator>
<dc:creator>Gerbrand J van der Heden van Noort</dc:creator>
<dc:creator>Julian D Langer</dc:creator>
<dc:creator>Andreas Weigert</dc:creator>
<dc:creator>J Wade Harper</dc:creator>
<dc:creator>Joseph D Mancias</dc:creator>
<dc:creator>Ivan Dikic</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion</dc:title>
<dc:identifier>pmid:39481378</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.048</dc:identifier>
</item>
<item>
<title>Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39480381/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TAVR was not superior to AS surveillance for the primary hierarchical composite endpoint in patients with moderate AS and HFrEF on GDMT. Preemptive TAVR for moderate AS was safe and may provide clinically meaningful quality-of-life benefits.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)09960-1. doi: 10.1016/j.jacc.2024.10.070. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Neurohormonal modulation and afterload reduction are key for treatment of heart failure with reduced ejection fraction (HFrEF). In HFrEF patients with concomitant moderate aortic stenosis (AS), treatment with transcatheter aortic valve replacement (TAVR) may be complementary to guideline-directed medical therapy (GDMT).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine whether TAVR for moderate AS provides clinical benefit in patients with HFrEF on top of GDMT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed an investigator-initiated, international, randomized controlled trial in patients with HFrEF on GDMT with moderate AS who were suitable for transfemoral TAVR with a balloon-expandable valve. Patients were randomized 1:1 to TAVR or clinical aortic stenosis surveillance (CASS) with aortic valve replacement upon progression to severe AS. The primary endpoint was the hierarchical occurrence of: 1) all-cause death; 2) disabling stroke; 3) disease-related hospitalizations and heart failure equivalents; and 4) change from baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score analyzed using the win ratio.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From January 2017 to December 2022, 178 patients were randomized to TAVR (n = 89) or AS surveillance (n = 89). The mean age was 77 years, 20.8% were female, and 55.6% were in NYHA functional class III or IV. The median follow-up duration was 23 months (Q1-Q3: 12-33 months). A total of 38 (43%) patients in the CASS group (of whom 35 had progressed to severe AS) underwent TAVR at a median of 12 months postrandomization. TAVR was associated with wins in 47.6% of pairs, compared with 36.6% in the CASS group, resulting in a win ratio of 1.31 (95% CI: 0.91-1.88; P = 0.14). At 1 year, TAVR resulted in a greater improvement in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score compared with the CASS group (12.8 ± 21.9 points vs 3.2 ± 22.8 points; P = 0.018).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TAVR was not superior to AS surveillance for the primary hierarchical composite endpoint in patients with moderate AS and HFrEF on GDMT. Preemptive TAVR for moderate AS was safe and may provide clinically meaningful quality-of-life benefits.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39480381/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39480381</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.070>10.1016/j.jacc.2024.10.070</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39480381</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicolas M Van Mieghem</dc:creator>
<dc:creator>Sammy Elmariah</dc:creator>
<dc:creator>Ernest Spitzer</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Tamim M Nazif</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Alexandra Popma</dc:creator>
<dc:creator>Ori Ben-Yehuda</dc:creator>
<dc:creator>Faouzi Kallel</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Michael L Chuang</dc:creator>
<dc:creator>Maria C Alu</dc:creator>
<dc:creator>Wietze Lindeboom</dc:creator>
<dc:creator>Dhaval Kolte</dc:creator>
<dc:creator>Firas E Zahr</dc:creator>
<dc:creator>Susheel K Kodali</dc:creator>
<dc:creator>Justin A Strote</dc:creator>
<dc:creator>Renicus S Hermanides</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Jan G P Tijssen</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD</dc:title>
<dc:identifier>pmid:39480381</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.070</dc:identifier>
</item>
<item>
<title>Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39480380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Compared with OMT alone, treatment of patients with symptomatic and severe or greater TR with TTVR+OMT resulted in substantial improvement in patients' symptoms, function, and quality of life. These benefits were evident 30 days after TTVR, continued to increase through 6 months, and remained durable through 1 year. (TRISCEND II Pivotal Trial [Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)09954-6. doi: 10.1016/j.jacc.2024.10.067. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Severe tricuspid regurgitation (TR) often causes substantial impairment in patient-reported health status (ie, symptoms, physical and social function, and quality of life), which may improve with transcatheter tricuspid valve replacement (TTVR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We performed an in-depth analysis of health status of patients enrolled in the TRISCEND (Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device) II pivotal trial to help quantify the benefit of intervention to patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The TRISCEND II pivotal trial randomized 400 patients with symptomatic and severe or greater TR 2:1 to TTVR with the EVOQUE tricuspid valve replacement system plus optimal medical therapy (OMT) or OMT alone. Health status was assessed with the Kansas City Cardiomyopathy Questionnaire and the 36-Item Short Form Health Survey. Changes in health status over 1 year were compared between treatment groups using mixed-effects repeated-measures models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analysis cohort included 392 patients, of whom 259 underwent attempted TTVR and 133 received OMT alone (mean age 79.2 ± 7.6 years, 75.5% women, 56.1% with massive or torrential TR). Patients had substantially impaired health status at baseline (mean Kansas City Cardiomyopathy Questionnaire Overall Summary Score [KCCQ-OS] 52.1 ± 22.8; mean 36-Item Short Form Health Survey physical component summary score 35.2 ± 8.4). TTVR+OMT patients reported significantly greater improvement in both disease-specific and generic health status at each follow-up time point. Mean between-group differences in the KCCQ-OS favored TTVR+OMT at each time point: 11.8 points (95% CI: 7.4-16.3 points) at 30 days, 20.8 points (95% CI: 16.1-25.5 points) at 6 months, and 17.8 points (95% CI: 13.0-22.5 points) at 1 year. In subgroup analyses, TTVR+OMT improved health status to a greater extent among patients with torrential or massive TR vs severe TR (treatment effect 23.3 vs 22.6 vs 11.3; interaction P = 0.049). At 1 year, 64.6% of TTVR+OMT patients were alive and well (KCCQ-OS ≥60 points and no decline of ≥10 points from baseline) compared with 31.0% with OMT alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compared with OMT alone, treatment of patients with symptomatic and severe or greater TR with TTVR+OMT resulted in substantial improvement in patients' symptoms, function, and quality of life. These benefits were evident 30 days after TTVR, continued to increase through 6 months, and remained durable through 1 year. (TRISCEND II Pivotal Trial [Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device]; NCT04482062).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39480380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39480380</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.067>10.1016/j.jacc.2024.10.067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39480380</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Moody Makar</dc:creator>
<dc:creator>Rahul P Sharma</dc:creator>
<dc:creator>Christiane Haeffele</dc:creator>
<dc:creator>Charles J Davidson</dc:creator>
<dc:creator>Akhil Narang</dc:creator>
<dc:creator>Brian O'Neill</dc:creator>
<dc:creator>James Lee</dc:creator>
<dc:creator>Pradeep Yadav</dc:creator>
<dc:creator>Firas Zahr</dc:creator>
<dc:creator>Scott Chadderdon</dc:creator>
<dc:creator>Mackram Eleid</dc:creator>
<dc:creator>Sorin Pislaru</dc:creator>
<dc:creator>Robert Smith</dc:creator>
<dc:creator>Molly Szerlip</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:creator>Nishant Sekaran</dc:creator>
<dc:creator>Santiago Garcia</dc:creator>
<dc:creator>Terri Stewart-Dehner</dc:creator>
<dc:creator>Paul A Grayburn</dc:creator>
<dc:creator>Anna Sannino</dc:creator>
<dc:creator>Clayton Snyder</dc:creator>
<dc:creator>Yiran Zhang</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Susheel Kodali</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>TRISCEND II Pivotal Trial Investigators</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial</dc:title>
<dc:identifier>pmid:39480380</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.067</dc:identifier>
</item>
<item>
<title>Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39480379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The biodegradable polymer sirolimus-eluting stent was noninferior to currently used second-generation DES with regard to TLF at 1 year. (Firehawk® Rapamycin Target Eluting Coronary Stent North American Trial; NCT04562532).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 24:S0735-1097(24)09966-2. doi: 10.1016/j.jacc.2024.10.074. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Drug-eluting stents (DESs) with controlled antiproliferative drug release reduce restenosis risk, but durable polymers can delay healing and inhibit reendothelialization. The Firehawk biodegradable polymer sirolimus-eluting stent (BP-SES) has a fully biodegradable sirolimus-containing polymer coating localized to recessed abluminal grooves on the stent surface and delivers roughly one-third the drug dose of other DESs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We report the primary results of the TARGET-IV NA (Firehawk Rapamycin Target Eluting Coronary Stent North American Trial) randomized controlled trial comparing clinical outcomes with BP-SES vs currently used second-generation DESs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The TARGET-IV NA study was a prospective, multicenter, single-blind, 1:1 randomized noninferiority trial comparing the BP-SES with control in North America and Europe among patients undergoing percutaneous coronary intervention for chronic or acute coronary syndromes. The primary endpoint was target lesion failure (TLF) at 12 months (composite of cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization). The primary analysis (intention-to-treat) tested noninferiority of BP-SES vs control using an absolute margin of 3.85% and 1-sided α of 0.025. Noninferiority-powered secondary endpoints were tested in an optical coherence tomography substudy (endpoint: mean neointimal hyperplasia thickness) and an angiography substudy (endpoint: in-stent late lumen loss).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1,720 patients (mean age 66 years; 74% male) with 2,159 lesions were randomly allocated to receive either BP-SES (860 patients, 1,057 lesions) or control second-generation DES (860 patients, 1,084 lesions). A total of 61% of patients presented with stable coronary disease, 32% had unstable angina, and 7% had non-ST-segment elevation myocardial infarction (NSTEMI) or recent ST-segment elevation myocardial infarction. The rate of TLF with BP-SES was noninferior to control at 12 months (3.4% vs 3.3%, absolute risk difference 0.13%, upper bound 97.5% CI: 2.03, P<sub>noninferiority</sub> &lt; 0.0001). Cardiac death, myocardial infarction, and stent thrombosis rates were similar between groups. Angiographic follow-up was available in 104 patients (97.2% of those enrolled in the angiographic substudy) and 128 (94.1%) lesions. At 13 months, the powered secondary endpoint of mean in-stent late lumen loss was 0.149 ± 0.263 mm for BP-SES and 0.327 ± 0.463 mm for control (least squares mean difference: -0.178; 90% CI: -0.2943 to -0.0632; P<sub>noninferiority</sub> &lt; 0.0001). The optical coherence tomography substudy included 37 patients (42 lesions) with no difference in mean neointimal hyperplasia thickness between groups at 13 months (P<sub>noninferiority</sub> = 0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The biodegradable polymer sirolimus-eluting stent was noninferior to currently used second-generation DES with regard to TLF at 1 year. (Firehawk® Rapamycin Target Eluting Coronary Stent North American Trial; NCT04562532).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39480379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39480379</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.074>10.1016/j.jacc.2024.10.074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39480379</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Olivier F Bertrand</dc:creator>
<dc:creator>Ehtisham Mahmud</dc:creator>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Batla Falah</dc:creator>
<dc:creator>Melek Ozgu Issever</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Alexandra Popma</dc:creator>
<dc:creator>Michael Curtis</dc:creator>
<dc:creator>Niels van Royen</dc:creator>
<dc:creator>Jean-Francois Tanguay</dc:creator>
<dc:creator>Luc Janssens</dc:creator>
<dc:creator>William N Newman</dc:creator>
<dc:creator>Koen Teeuwen</dc:creator>
<dc:creator>James W Choi</dc:creator>
<dc:creator>Maurits T Dirksen</dc:creator>
<dc:creator>Akiko Maehara</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial</dc:title>
<dc:identifier>pmid:39480379</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.074</dc:identifier>
</item>
<item>
<title>Drug-Coated Balloon Angioplasty of the Side Branch During Provisional Stenting: The Multicenter Randomized DCB-BIF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39480378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with simple and true coronary bifurcation lesions undergoing provisional stenting, main vessel stenting with a DCB for the compromised side branch resulted in a lower 1-year rate of the composite outcome compared with an NCB intervention for the side branch. The high rates of periprocedural myocardial infarction, which occurred early and did not lead to revascularization, are of unclear clinical significance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)08451-1. doi: 10.1016/j.jacc.2024.08.067. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Side branch stenting is often required during provisional stenting, leading to suboptimal results. Drug-coated balloons (DCB) for the compromised side branch have emerged as an attractive strategy. However, the benefit of DCB for coronary bifurcations remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to investigate whether DCB, compared with a noncompliant balloon (NCB), for the pinched side branch improves the outcomes of provisional stenting in patients with simple, true coronary bifurcations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this multicenter, randomized controlled trial, patients with true coronary bifurcations who had side branch diameter stenosis of ≥70% after main vessel stenting at 22 centers in China, Indonesia, Italy, and Korea were randomly assigned to either DCB or NCB intervention. The primary endpoint was major adverse cardiac events, a composite of cardiac death, target vessel myocardial infarction, or clinically driven target-lesion revascularization at the 1-year follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between September 8, 2020, and June 2, 2023, 784 patients with true coronary bifurcation lesions undergoing main vessel stenting and having a severely compromised side branch were randomly assigned to the DCB (n = 391) or NCB (n = 393) group. One-year follow-up was completed in all patients. The primary endpoint occurred in 28 patients in the DCB group and 49 patients in the NCB group (Kaplan-Meier rate: 7.2% vs 12.5%; HR: 0.56; 95% CI: 0.35-0.88; P = 0.013), driven by a reduction in myocardial infarction. There were no significant differences between groups in procedural success, crossover to a 2-stent approach, all-cause death, revascularization, or stent thrombosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with simple and true coronary bifurcation lesions undergoing provisional stenting, main vessel stenting with a DCB for the compromised side branch resulted in a lower 1-year rate of the composite outcome compared with an NCB intervention for the side branch. The high rates of periprocedural myocardial infarction, which occurred early and did not lead to revascularization, are of unclear clinical significance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39480378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39480378</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.067>10.1016/j.jacc.2024.08.067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39480378</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaofei Gao</dc:creator>
<dc:creator>Nailiang Tian</dc:creator>
<dc:creator>Jing Kan</dc:creator>
<dc:creator>Ping Li</dc:creator>
<dc:creator>Mian Wang</dc:creator>
<dc:creator>Imad Sheiban</dc:creator>
<dc:creator>Filippo Figini</dc:creator>
<dc:creator>Jianping Deng</dc:creator>
<dc:creator>Xiang Chen</dc:creator>
<dc:creator>Teguh Santoso</dc:creator>
<dc:creator>Eun-Seok Shin</dc:creator>
<dc:creator>Muhammad Munawar</dc:creator>
<dc:creator>Shangyu Wen</dc:creator>
<dc:creator>Zhengzhong Wang</dc:creator>
<dc:creator>Shaoping Nie</dc:creator>
<dc:creator>Yue Li</dc:creator>
<dc:creator>Tan Xu</dc:creator>
<dc:creator>Bin Wang</dc:creator>
<dc:creator>Fei Ye</dc:creator>
<dc:creator>Junjie Zhang</dc:creator>
<dc:creator>Xiling Shou</dc:creator>
<dc:creator>Shao-Liang Chen</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Drug-Coated Balloon Angioplasty of the Side Branch During Provisional Stenting: The Multicenter Randomized DCB-BIF Trial</dc:title>
<dc:identifier>pmid:39480378</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.067</dc:identifier>
</item>
<item>
<title>Drug-Coated Balloons to Keep Interventions of the Side Branch Simple (KISS): KISS or Be KISS'D</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39480377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)08517-6. doi: 10.1016/j.jacc.2024.09.020. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39480377/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39480377</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.020>10.1016/j.jacc.2024.09.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39480377</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ziad Ali</dc:creator>
<dc:creator>Celina M Yong</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Drug-Coated Balloons to Keep Interventions of the Side Branch Simple (KISS): KISS or Be KISS'D</dc:title>
<dc:identifier>pmid:39480377</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.020</dc:identifier>
</item>
<item>
<title>Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy: Can Aficamten Stand Alone?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39477632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 5;84(19):1850-1853. doi: 10.1016/j.jacc.2024.09.015.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39477632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39477632</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.015>10.1016/j.jacc.2024.09.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39477632</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Enrico Ammirati</dc:creator>
<dc:creator>Guglielmo Gallone</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy: Can Aficamten Stand Alone?</dc:title>
<dc:identifier>pmid:39477632</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.015</dc:identifier>
</item>
<item>
<title>Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39477631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In FOREST-HCM, one-half of the patients with oHCM attempted downtitration and withdrawal of SoC medications while receiving aficamten treatment, with infrequent instances of resumption of SoC. Stopping and dose reduction of SoC medications were well tolerated with no adverse consequences in clinical measures of efficacy (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 5;84(19):1839-1849. doi: 10.1016/j.jacc.2024.09.002.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Standard-of-care (SoC) medications for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) are recommended as first-line therapy despite the lack of evidence from controlled clinical trials and well known off-target side effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We describe the impact of SoC therapy downtitration and withdrawal in patients already receiving aficamten in FOREST-HCM (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy; NCT04848506).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients receiving SoC therapy (beta-blocker, nondihydropyridine calcium-channel blocker, and/or disopyramide) were eligible for protocol-guided SoC downtitration and withdrawal at the discretion of the investigator and after achieving a stable dose of aficamten for ≥4 weeks. Successful SoC withdrawal was defined as at least a 50% dose-reduction in ≥1 medication. Adverse events (AEs) were prospectively evaluated 1 to 2 weeks after any SoC withdrawal.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 145 patients with oHCM who were followed for at least 24 weeks (mean age 60.5 ± 13.2 years; 44.8% female; 42% NYHA functional class III), 136 (93.8%) were receiving ≥1 SoC therapy; of those, 64 (47%) had an attempt at withdrawal, with 59 (92.2%) successful. Thirty-eight (64.4%) patients completely discontinued ≥1 medication, and 27 (45.8%) achieved aficamten monotherapy with 2 later restarting a SoC medication. There were no significant differences in baseline characteristics on day 1 in FOREST-HCM in those with a SoC-withdrawal vs no-withdrawal attempt. In patients who underwent successful SoC therapy withdrawal, NYHA functional class improved by ≥1 class in 79.2% from baseline, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score improved to 83.0 ± 15.8 points, and resting and Valsalva left ventricular outflow tract gradient improved to 14.3 ± 10.9 and 32.9 ± 21.4 mm Hg, respectively. N-terminal pro-B-type natriuretic peptide levels improved to a median of 220.0 pg/mL (Q1-Q3: 102.0-554.0.0 pg/mL) and high-sensitivity troponin I improved to a median of 6.0 ng/L (Q1-Q3:3.5-10.7 ng/L). Downtitration and withdrawal of SoC therapy did not impact these results (all P values for change were >;0.05), and these changes were similar in patients who did not undergo SoC therapy withdrawal. There were no serious AEs attributed to SoC withdrawal and treatment emergent AEs were similar between groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In FOREST-HCM, one-half of the patients with oHCM attempted downtitration and withdrawal of SoC medications while receiving aficamten treatment, with infrequent instances of resumption of SoC. Stopping and dose reduction of SoC medications were well tolerated with no adverse consequences in clinical measures of efficacy (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39477631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39477631</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.002>10.1016/j.jacc.2024.09.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39477631</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Lubna Choudhury</dc:creator>
<dc:creator>Roberto Barriales-Villa</dc:creator>
<dc:creator>Perry Elliott</dc:creator>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Michael E Nassif</dc:creator>
<dc:creator>Artur Oreziak</dc:creator>
<dc:creator>Anjali Tiku Owens</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Albree Tower-Rader</dc:creator>
<dc:creator>Florian Rader</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Sherif F Nagueh</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:creator>Stephen B Heitner</dc:creator>
<dc:creator>Daniel L Jacoby</dc:creator>
<dc:creator>Stuart Kupfer</dc:creator>
<dc:creator>Fady I Malik</dc:creator>
<dc:creator>Chiara Melloni</dc:creator>
<dc:creator>Lisa Meng</dc:creator>
<dc:creator>Jenny Wei</dc:creator>
<dc:creator>Mark V Sherrid</dc:creator>
<dc:creator>Theodore P Abraham</dc:creator>
<dc:creator>FOREST-HCM Investigators</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM</dc:title>
<dc:identifier>pmid:39477631</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.002</dc:identifier>
</item>
<item>
<title>TAVR in Patients with Moderate Aortic Stenosis and Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39477044/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241104111323&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)10056-3. doi: 10.1016/j.jacc.2024.10.088. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39477044/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241104111323&v=2.18.0.post9+e462414">39477044</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.088>10.1016/j.jacc.2024.10.088</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39477044</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Philippe Généreux</dc:creator>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>TAVR in Patients with Moderate Aortic Stenosis and Heart Failure</dc:title>
<dc:identifier>pmid:39477044</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.088</dc:identifier>
</item>





























</channel>
</rss>